Naurex Secures $18,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=1a50c0f9-fffe-4173-99f6-480a9a6c4c27&Preview=1 - Date
5/11/2011 - Company Name
Naurex - Mailing Address
1801 Maple Ave. Evanston, IL 60201 - Company Description
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). - Website
http://www.naurex.com - Transaction Type
Venture Equity - Transaction Amount
$18,000,000 - Transaction Round
Series A - Proceeds Purposes
Naurex will use the proceeds from the Series A financing primarily for the Phase II trial of its lead compound, GLYX-13, a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor (NMDAR), and also to advance its second-generation GFPA program. - M&A Terms
- Venture Investor
Adams Street Partners - Venture Investor
Latterell Venture Partners - Venture Investor
Takeda Ventures - Venture Investor
Shire Pharmaceuticals - Venture Investor
Undisclosed
